Physician profile
Alejandro Lopez
NPI 1962498121
$5,801.39
in general payments reported to CMS, 2019-2025
29 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $662 · 2021: $761 · 2022: $765 · 2023: $1,021 · 2024: $991 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490 · Education: $39.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.94 |
| Education | $39.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,458.33 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,055.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $662.59 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $409.13 | 2019-2022 | |
| Amgen INC. | $352.69 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $308.66 | 2019-2023 | Myrbetriq, Veozah |
| Novartis Pharmaceuticals Corporation | $249.54 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.83 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $195.00 | 2019-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $189.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $164.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $93.73 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $88.90 | 2019-2022 | |
| Esperion Therapeutics, INC. | $46.52 | 2021-2024 | Nexletol |
| Alk-Abello, INC | $41.94 | 2024 | Grastek, Ragwitek, Odactra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.88 | 2019 | |
| Arbor Pharmaceuticals, INC. | $34.55 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.39 | 2024 | Rexulti |
| Genentech USA, INC. | $23.52 | 2021 | |
| Eisai INC. | $19.05 | 2021 | |
| Abbvie INC. | $18.46 | 2021 | |
| Dexcom, INC. | $16.94 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $16.78 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.59 | 2025 | Keveyis |
| Sanofi Pasteur INC. | $15.33 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.99 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $14.57 | 2020 | |
| Medtronic USA, INC. | $12.56 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.